Khadijeh Abhari1, Saeede Saadati1, Zahra Yari1, Hedayat Hosseini2, Mehdi Hedayati3, Shahabeddin Abhari4, Seyyed Moayyed Alavian5, Azita Hekmatdoost6. 1. Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology, Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 2. Department of Food Technology, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology, Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 3. Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 4. Amol Faculty of Paramedical Sciences, Mazandaran University of Medical Sciences, Sari, Iran. 5. Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran. 6. Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology, Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: a_hekmat2000@yahoo.com.
Abstract
BACKGROUND: The aim of this study was to evaluate the effects of supplementation with 109 spores of Bacillus coagulans (GBI-30) plus inulin in patients with non-alcoholic fatty liver disease (NAFLD). METHODS: In a randomized, double-blind, placebo-controlled clinical trial, fifty three patients with NAFLD were randomly assigned to receive either a synbiotic or a placebo capsule for 12 weeks. The primary outcome was reduction in steatosis score in Fibroscan exam. RESULTS: At the end of study, serum alanine aminotransferase and γ glutamine transaminase decreased significantly more in synbiotic group compared to placebo group (p = 0.001, and p = 0.004, respectively). Synbiotic supplementation significantly reduced serum tumor necrosis factor-α (p = 0.03) and nuclear factor-κB activity (p = 0.04). Moreover, hepatic steatosis reduced significantly more in synbiotic group compared to placebo group (p < 0.001). CONCLUSION: Our results indicate that 12 weeks supplementation with B. coagulans plus inulin is beneficial for treatment of NAFLD and its related inflammation without any significant effects on related cardiovascular risk factors. CLINICAL TRIALS: This trial was registered at irct.ir with number of IRCT20100524004010N23.
RCT Entities:
BACKGROUND: The aim of this study was to evaluate the effects of supplementation with 109 spores of Bacillus coagulans (GBI-30) plus inulin in patients with non-alcoholic fatty liver disease (NAFLD). METHODS: In a randomized, double-blind, placebo-controlled clinical trial, fifty three patients with NAFLD were randomly assigned to receive either a synbiotic or a placebo capsule for 12 weeks. The primary outcome was reduction in steatosis score in Fibroscan exam. RESULTS: At the end of study, serum alanine aminotransferase and γ glutamine transaminase decreased significantly more in synbiotic group compared to placebo group (p = 0.001, and p = 0.004, respectively). Synbiotic supplementation significantly reduced serum tumor necrosis factor-α (p = 0.03) and nuclear factor-κB activity (p = 0.04). Moreover, hepatic steatosis reduced significantly more in synbiotic group compared to placebo group (p < 0.001). CONCLUSION: Our results indicate that 12 weeks supplementation with B. coagulans plus inulin is beneficial for treatment of NAFLD and its related inflammation without any significant effects on related cardiovascular risk factors. CLINICAL TRIALS: This trial was registered at irct.ir with number of IRCT20100524004010N23.
Authors: Yuanshe Huang; Xiaodong Wang; Lai Zhang; Ke Zheng; Jie Xiong; Jing Li; Chunlei Cong; Zhaomiao Gong; Jingxin Mao Journal: Comput Math Methods Med Date: 2022-05-30 Impact factor: 2.809
Authors: Małgorzata Moszak; Monika Szulińska; Marta Walczak-Gałęzewska; Paweł Bogdański Journal: Int J Environ Res Public Health Date: 2021-02-08 Impact factor: 3.390
Authors: Rodrigo Zamignan Carpi; Sandra M Barbalho; Katia Portero Sloan; Lucas Fornari Laurindo; Heron Fernando Gonzaga; Paulo Cesar Grippa; Tereza L Menegucci Zutin; Raul J S Girio; Cláudia Sampaio Fonseca Repetti; Cláudia Rucco Penteado Detregiachi; Patrícia C Santos Bueno; Eliana de Souza Bastos Mazuqueli Pereira; Ricardo de Alvares Goulart; Jesselina Francisco Dos Santos Haber Journal: Int J Mol Sci Date: 2022-08-08 Impact factor: 6.208
Authors: Oluyemi Komolafe; Elena Buzzetti; Audrey Linden; Lawrence Mj Best; Angela M Madden; Danielle Roberts; Thomas Jg Chase; Dominic Fritche; Suzanne C Freeman; Nicola J Cooper; Alex J Sutton; Elisabeth Jane Milne; Kathy Wright; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy Journal: Cochrane Database Syst Rev Date: 2021-07-19